Epigenomics AG (STU:ECX) Short-Term Capital Lease Obligation : €0.23 Mil (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG Short-Term Capital Lease Obligation?

Epigenomics AG's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.23 Mil.

Epigenomics AG's quarterly Short-Term Capital Lease Obligation declined from Dec. 2022 (€0.32 Mil) to Mar. 2023 (€0.26 Mil) and declined from Mar. 2023 (€0.26 Mil) to Jun. 2023 (€0.23 Mil).

Epigenomics AG's annual Short-Term Capital Lease Obligation declined from Dec. 2020 (€0.22 Mil) to Dec. 2021 (€0.09 Mil) but then increased from Dec. 2021 (€0.09 Mil) to Dec. 2022 (€0.32 Mil).

Epigenomics AG Short-Term Capital Lease Obligation Historical Data

The historical data trend for Epigenomics AG's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Short-Term Capital Lease Obligation Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.22

0.09

0.32

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.31	0.34	0.32	0.26	0.23

Epigenomics AG Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Epigenomics AG Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (STU:ECX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

EPGNF:USA

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.